Three Years of Daily Use: ALS BCI Moves from Lab Milestone to Clinical Baseline
Casey Harrell's multi-year BCI use record reframes speech-restoration implants as durable daily tools, raising the stakes for Neuralink and Synchron.
8. Three Years of Daily Use: ALS BCI Moves from Lab Milestone to Clinical Baseline
Casey Harrell, a man living with ALS-related paralysis, has logged thousands of hours using a brain-computer interface to produce speech over roughly three years of continuous use. Electrodes embedded in his brain capture motor-cortex signals; decoding software translates those signals into words in near real time. The MIT Technology Review profile, published June 2026, marks the longest sustained real-world BCI speech-use record reported in mainstream scientific coverage, and Harrell has graduated from supervised research sessions to independent, daily operation.
That durability record matters competitively. Neuralink's N1 implant and Synchron's Stentrode have both posted headline demonstrations, but neither company has published multi-year daily-use data from a single patient at this scale. Harrell's case, developed through academic research rather than a commercial product, now sets an implicit performance bar: sustained reliability over years, not weeks. Any BCI company seeking FDA Breakthrough Device clearance or Medicare reimbursement will face the question of whether their system matches this baseline. The gap between a compelling demo and a credible clinical instrument just got quantified in calendar time.
The broader pattern is a shift in what counts as proof. Early BCI coverage treated any decoded sentence as news. The field is now past that threshold. Investors and regulators are starting to ask about electrode longevity, decoding drift, and caregiver burden across years of use. Harrell's profile arrives as Neuralink targets expanded trial enrollment and Synchron pursues commercial partnerships with hospital systems. Watch whether either company responds with longitudinal data of their own, or whether the academic research pipeline continues to set the evidentiary standard that commercial players have to chase.
Source: MIT Technology Review